Literature DB >> 33261917

Smoking and COVID-19, the paradox to discover: An Italian retrospective, observational study in hospitalized and non-hospitalized patients.

Carlo Lombardi1, Elena Roca2, Laura Ventura3, Marcello Cottini4.   

Abstract

Entities:  

Keywords:  COVID-19 disease; SARS-CoV2; Smoking

Year:  2020        PMID: 33261917      PMCID: PMC7659913          DOI: 10.1016/j.mehy.2020.110391

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


× No keyword cloud information.
We have read with great interest the article published on Medical Hypotheses by de Bernardis & Busà about the putative role for the tobacco mosaic virus in smokers’ resistance to COVID-19 [1]. We agree with the Authors and we also believe that smoking has a complex and not yet clear link with COVID-19. We considered 2 cohorts of 601 patients from 2 Northern Italian cities (Brescia and Bergamo) most affected by the SARS-CoV-2 infection: one concerning patients admitted to our hospital in Brescia, and another one concerning non-hospitalized patients evaluated at the territorial medicine level in Bergamo. The aim of the study was to assess whether or not there was a correlation between current active smoking and severity of COVID-19 disease. 299 consecutive hospitalized COVID-19 patients (M/F = 208 (70%)/ 91(30%) were included and among these 46 (15%) were current active smokers. The mean age was 68.8 years (±11.7). The patients who died as a consequence of COVID-19 disease were 87 (29%). Table 1 shows that active smoking and COVID-19 are independent variables (p-value = 0.99) in our hospitalized patients. Garufi et al. claim that the current available data on the relationship between COVID-19 and smoking only concern hospitalized patients [2]. In our study 302 consecutive non-hospitalized COVID-19 patients (M/F = 176 (58.3%) /126 (41.7%) were also included and among these 92 (30%) were current active smokers. The non-hospitalized patients who died as a result of COVID-19 disease were 28 (9.3%). The table I shows that current active smoking and COVID-19 were independent variables (p-value = 0.66) also for non-hospitalized patients. These data are in line with the results of the study performed by Meini et al. and Lippi et al. that reported an unexpectedly low prevalence of current smokers among COVID-19 hospitalized patients [3], [4]. We agree with the Authors and we also found no significant correlation between active smoking and severity of COVID-19 disease. We believe that our study can add important information about the link between smoking and COVID-19 in Italian hospitalized and non-hospitalized patients too.
Table 1

See text.

PatientsVariableDeathsOR95% CI ORP-value
HospitalizedSmokingNo 0.280Yes 0.2831.01(0.45;2.18)0.99
Not-hospitalizedSmokingNo 0.310Yes 0.2500.74(0.26;1.89)0.66
See text. Probably the link between smoking and COVID-19 is not simple and does not concern a single factor. If it is true that smoking increases the expression of ACE2 receptors to which the SARS-Cov-2 attaches, it is equally true that up regulation of this enzyme can decrease the risk of developing serious systemic complications of coronavirus infection [5], [6]. This is due to the fact that ACE2 converts angiotensin II (ANG II) to Angiotensin 1–7 (ANG 1–7) thus decreasing the powerful pro inflammatory effect of ANG II [7], [8]. Other Authors have confirmed that ACE2 mitigates pro inflammatory effects by decreasing the circulating amount of ANG II [9]. Moreover, studies in mice have shown that in smokers there is an upregulation of ACE2 which protects from the development of the Acute Respiratory Distress Syndrome (ARDS) [10], [11]. Consequently, studies have hypothesized that the up-regulation of this enzyme may protect patients from severe lung damage and that this also occurs in patients with COVID-19 [11]. Although it seems like a paradox, the latest scientific evidences are in favour of the hypothesis that smoking is not associated with the severity of COVID-19 patients. Our case series is interesting because it reports the data of hospitalized and non-hospitalized patients, confirming the non-association between smoking and COVID-19 disease. Future studies will be need to confirm this hypothesis and to discover the underlying pathophysiological mechanisms.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  10 in total

1.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Authors:  Akram Khan; Cody Benthin; Brian Zeno; Timothy E Albertson; John Boyd; Jason D Christie; Richard Hall; Germain Poirier; Juan J Ronco; Mark Tidswell; Kelly Hardes; William M Powley; Tracey J Wright; Sarah K Siederer; David A Fairman; David A Lipson; Andrew I Bayliffe; Aili L Lazaar
Journal:  Crit Care       Date:  2017-09-07       Impact factor: 9.097

2.  Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.

Authors:  Giovanna Garufi; Luisa Carbognin; Armando Orlandi; Giampaolo Tortora; Emilio Bria
Journal:  Eur J Intern Med       Date:  2020-04-23       Impact factor: 4.487

3.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

4.  A putative role for the tobacco mosaic virus in smokers' resistance to COVID-19.

Authors:  E de Bernardis; L Busà
Journal:  Med Hypotheses       Date:  2020-07-31       Impact factor: 1.538

5.  Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.

Authors:  David Gurwitz
Journal:  Drug Dev Res       Date:  2020-03-04       Impact factor: 5.004

Review 6.  Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Carme Perez-Quilis; Brandon M Henry; Giuseppe Lippi
Journal:  Mayo Clin Proc       Date:  2020-04-04       Impact factor: 7.616

7.  ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19.

Authors:  Janice M Leung; Chen X Yang; Anthony Tam; Tawimas Shaipanich; Tillie-Louise Hackett; Gurpreet K Singhera; Delbert R Dorscheid; Don D Sin
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

8.  Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19).

Authors:  Giuseppe Lippi; Brandon Michael Henry
Journal:  Eur J Intern Med       Date:  2020-03-16       Impact factor: 4.487

Review 9.  The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice.

Authors:  Yumiko Imai; Keiji Kuba; Josef M Penninger
Journal:  Exp Physiol       Date:  2008-04-10       Impact factor: 2.969

10.  The Paradox of the Low Prevalence of Current Smokers Among COVID-19 Patients Hospitalized in Nonintensive Care Wards: Results From an Italian Multicenter Case-Control Study.

Authors:  Simone Meini; Alberto Fortini; Roberto Andreini; Leonardo Alberto Sechi; Carlo Tascini
Journal:  Nicotine Tob Res       Date:  2021-08-04       Impact factor: 4.244

  10 in total
  5 in total

1.  Association of smoking and cardiovascular disease with disease progression in COVID-19: A systematic review and meta-analysis.

Authors:  Shiwei Kang; Xiaowei Gong; Yadong Yuan
Journal:  Epidemiol Infect       Date:  2021-05-12       Impact factor: 2.451

Review 2.  COVID-19 and Dentistry in 72 Questions: An Overview of the Literature.

Authors:  Stéphane Derruau; Jérôme Bouchet; Ali Nassif; Alexandre Baudet; Kazutoyo Yasukawa; Sandrine Lorimier; Isabelle Prêcheur; Agnès Bloch-Zupan; Bernard Pellat; Hélène Chardin; Sophie Jung
Journal:  J Clin Med       Date:  2021-02-16       Impact factor: 4.241

3.  A 2-month post-COVID-19 follow-up study on patients with dyspnea.

Authors:  Md Khairul Islam; Mohammad Faisal Hossain; Md Maruf Ahmed Molla; Md Mohiuddin Sharif; Pratyay Hasan; Fahima Sharmin Hossain; Ayesha Sikder; Md Gias Uddin; Md Robed Amin
Journal:  Health Sci Rep       Date:  2021-11-17

4.  A possible protective role for Bacillus Calmette-Guérin therapy in urinary bladder cancer in the era of COVID-19: a brief report.

Authors:  Solmaz Ohadian Moghadam; Behzad Abbasi; Ali Nowroozi; Erfan Amini; Mohammad Reza Nowroozi; Seyed Ali Momeni; Hassan Niroomand
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31

Review 5.  Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID‑19 (Review).

Authors:  Sergej Nadalin; Hrvoje Jakovac; Vjekoslav Peitl; Dalibor Karlović; Alena Buretić-Tomljanović
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.